ViiV Healthcare

ViiV Healthcare is an England-based biotechnological company that develops and commercializes therapeutics for the treatment of HIV/AIDS. Read more

Deborah Waterhouse's photo - CEO of ViiV Healthcare

CEO

Deborah Waterhouse

CEO Approval Rating

83/100

Founded:

2009

Status:

VIIV HEALTHCARE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Aelix Therapeutics is ViiV Healthcare's top competitor. Aelix Therapeutics is headquartered in Barcelona, Barcelona, and was founded in 2014. Aelix Therapeutics is in the Health Care Services field. Aelix Therapeutics generates 1.15% the revenue of ViiV Healthcare.

Advaxis is seen as one of ViiV Healthcare's top competitors. Advaxis's headquarters is in Monmouth Junction, New Jersey, and was founded in 2002. Like ViiV Healthcare, Advaxis also operates in the Pharmaceuticals field. Advaxis generates 0.67% of ViiV Healthcare's revenue.

OyaGen has been one of ViiV Healthcare's top competitors. OyaGen was founded in 2003, and its headquarters is in Henrietta, New York. OyaGen competes in the Health Care Services industry. OyaGen has 1,089 fewer employees than ViiV Healthcare.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Merck a competitor of ViiV Healthcare?

ViiV Healthcare Acquisitions

No recent acquisitions found related to ViiV Healthcare

ViiV Healthcare Funding History

No recent funding data found related to ViiV Healthcare

ViiV Healthcare Investments

No recent investments found related to ViiV Healthcare

ViiV Healthcare News

March 11, 2021Pharmabiz

ViiV Healthcare presents positive data from phase IIa proofofconcept study of GSK3640254 to treat HIV at CROI 2021 conference

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shiono... See more »
March 9, 2021CompanyNews HQ

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV | GSK

For media and investors only Issued: London, UK The phase IIa proof-of-concept findings from ViiV Hea... See more »
March 6, 2021CompanyNews HQ

ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks | GSK

For media and investors only Issued: London UK Long-term efficacy and safety data from the phase IIIb... See more »
February 27, 2021Pharmabiz

ViiV Healthcare submits sNDA to US FDA for expanded use of Cabenuva to treat HIV

ViiV Healthcare announced that a supplemental New Drug Application (sNDA) has been submitted to the U... See more »
February 10, 2021PharmaTimes

ViiV's Rukobia wins EU authorisation to treat multidrug-resistant HIV

Rukobia is a first-in-class HIV attachment inhibitor... See more »

ViiV Healthcare Press Releases

May 15, 2019GlobeNewswire

Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

BEDMINSTER, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB)... See more »
April 26, 2019PressReleasePoint

ViiV Healthcare announces CHMP Positive Opinion for Dovato (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

Recommendation based on landmark GEMINI 1 & 2 studies which demonstrated non-inferior efficacy of dol... See more »
September 18, 2018WebWire

ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV

ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the Euro... See more »
July 24, 2018WebWire

Pfizer-backed ViiV prevents children with HIV from getting medicines they need

As the annual global HIV/AIDS conference kicks off in Amsterdam, the international medical humanitari... See more »
March 23, 2018StreetInsider

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer In... See more »
September 4, 2017CSRwire

ViiV Healthcare Awards $1 Million in Grants for Positive Action for Women in the U.S.

ViiV Healthcare announced $1 million in grants for Positive Action for Women (PAFW), a pilot initiati... See more »

ViiV Healthcare Videos

Social Media

ViiV Healthcare Headquarters

980 Great West Road

Brentford, EnglandTW8 9GS

44-20-838-06200

Driving Directions »

Trending Companies

ViiV Healthcare Summary

ABOUT

Overview

ViiV Healthcare is an England-based biotechnological company that develops and commercializes therapeutics for the treatment of HIV/AIDS. ViiV Healthcare was founded in 2009. ViiV Healthcare's headquarters is located in Brentford, England, GB TW8 9GS....

CEO

ViiV Healthcare's CEO, Deborah Waterhouse, currently has an approval rating of 83%. ViiV Healthcare's primary competitors are Aelix Therapeutics, Advaxis & OyaGen.

Frequently Asked Questions about ViiV Healthcare

  1. When was ViiV Healthcare founded?

    ViiV Healthcare was founded in 2009
  2. Who is ViiV Healthcare's CEO?

    ViiV Healthcare's CEO is Deborah Waterhouse
  3. How much revenue does ViiV Healthcare generate?

    ViiV Healthcare generates $347.7M in revenue
  4. How much funding does ViiV Healthcare have?

    ViiV Healthcare has historically raised $0 in funding
  1. Where is ViiV Healthcare's headquarters?

    ViiV Healthcare's headquarters is in Brentford England, GB
  2. How many employees does ViiV Healthcare have?

    ViiV Healthcare has 1,100 employees
  3. What sector does ViiV Healthcare operate in?

    ViiV Healthcare is in Pharmaceuticals, Biotechnology
  4. Who are ViiV Healthcare's competitors?

    ViiV Healthcare's top competitors are Aelix Therapeutics, Advaxis, OyaGen